Inhibitors of RAC1 and uses thereof for treating cancers

US11795144B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11795144-B2
Application numberUS-201816619311-A
CountryUS
Kind codeB2
Filing dateJun 6, 2018
Priority dateJun 6, 2017
Publication dateOct 24, 2023
Grant dateOct 24, 2023

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention concerns a compound having the following formula (I): wherein: A is in particular —N(R′ a )—C(═O)—R, R′ a being H or a (C 1 -C 6 )alkyl group, and R being preferably a group having the following formula (II): X is in particular chosen from the group consisting of: —SO 2 —N(R′ b )—, R′ b being H or a (C 1 -C 6 )alkyl group, —N(R″ b )—SO 2 —, R″ b being H or a (C 1 -C 6 )alkyl group, —CO—NH—, and —NH—CO—, for use for the treatment of cancers, such as metastatic cancers.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for the treatment of cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound having the following formula (VII): wherein: p is an integer from 1 to 3 inclusive; X′ is chosen from the group consisting of: —S—, —NH—, —NR d —, —CH 2 —, —SO 2 —, and —SO—, R d being H or a (C 1 -C 6 )alkyl group; R 5 is a (C 1 -C 6 )alkyl group; and the R 4 groups, identical or different, are chosen from the (C 1 -C 6 )alkyl groups. 2. The method of claim 1 , wherein X′ is —CH 2 —or —S—. 3. The method of claim 1 , wherein the compound of formula (VII) is the following compound: 4. (Allowed) The method of claim 1 , wherein the cancer is breast cancer.

Assignees

Inventors

Classifications

  • C07C311/29Primary

    having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring · CPC title

  • Antineoplastic agents · CPC title

  • C07C311/21Primary

    having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring · CPC title

  • having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring · CPC title

  • specific for metastasis · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11795144B2 cover?
The present invention concerns a compound having the following formula (I): wherein: A is in particular —N(R′ a )—C(═O)—R, R′ a being H or a (C 1 -C 6 )alkyl group, and R being preferably a group having the following formula (II): …
Who is the assignee on this patent?
Inst Nat Sante Rech Med, Centre Nat Rech Scient, Univ Nantes, and 1 more
What technology area does this patent fall under?
Primary CPC classification C07C311/29. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).